Comparative Pharmacology
Head-to-head clinical analysis: AMABELZ versus ZOVIA 1 35E 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMABELZ versus ZOVIA 1 35E 28.
AMABELZ vs ZOVIA 1/35E-28
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AMABELZ (amenamevir) is a helicase-primase inhibitor that inhibits the viral DNA replication by targeting the helicase-primase complex (UL5/UL52) of herpes simplex virus (HSV) and varicella-zoster virus (VZV).
ZOVIA 1/35E-28 is a combined oral contraceptive (COC) containing ethinyl estradiol and norethindrone. It inhibits ovulation via suppression of gonadotropins (FSH and LH), increases cervical mucus viscosity, and alters endometrial receptivity.
100 mg orally once daily.
One tablet orally once daily at the same time each day for 21 days, followed by 7 days of placebo (inactive tablets), then repeat.
None Documented
None Documented
Terminal half-life of 4-6 hours; clinically relevant for dosing interval of 8-12 hours in normal renal function.
Ethinyl estradiol: ~17 hours (range 13-27 hours); Norethindrone: ~8 hours (range 5-14 hours). Clinical context: Steady state achieved in ~5-7 days; contraceptive effect requires consistent dosing.
Primarily renal (70-80% unchanged), with minor biliary/fecal elimination (10-15%).
Renal: ~40% as metabolites; biliary/fecal: ~40% as metabolites; unchanged drug minimal (<1%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive